Oppenheimer more bullish on Alcon, upgrades to Outperform

As previously reported, Oppenheimer analyst Steven Lichtman upgraded Alcon to Outperform from Perform with a $103 price target. The firm says that following a firm 1Q, several new drivers are coming into view, namely a new opportunity in glaucoma with the announced acquisition of BELKIN Vision, approval of two enhancements to PanOptix IOL, significant new capital upgrade cycle opportunity beginning later this year in Surgical, and market share opportunity in AT-IOLs in China following a VBP win.